



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/688,089	10/16/2000	Hans J. Hansen	18733/1002	2717

7590 07/09/2002 /

FOLEY & LARDNER
Suite 500
3000 K Street, N.W.
P.O. Box 25696
Washington, DC 20007-8696

EXAMINER

HUFF, SHEELA JITENDRA

ART UNIT	PAPER NUMBER
1642	13

DATE MAILED: 07/09/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Applicant No.	Applicant(s)
	09/688,089	HANSEN, HANS J.
Examiner	Art Unit	
Sheela J Huff	1642	

— The MAILING DATE of this communication appears on the cover sheet with the corresponding address —

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 13 June 2002.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 48-57 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 48-57 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.

4) Interview Summary (PTO-413) Paper No(s) _____.

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____

DETAILED ACTION

Response to Amendment

The amendment filed on 6/13/02 has been considered.

Claims 48-57 are pending.

The IDS filed 4/26/02 has been considered and an initialed copy of the PTO-1449 is enclosed.

Response to Arguments

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 48-57 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-2 of U.S. Patent No. 6132718. Since claims 48-57 are the same as 30-37, claims 48-57 are subject to the same rejection as indicated in paper no. 6, mailed 10/26/01.

Applicant indicates that they will appropriately address this rejection when allowable subject matter is indicated. Applicant indicates that the claims are not obvious over the patent. However, applicant does not provide any reasons why. Applicant is also advised that no claims will be deemed allowable unless they are free from **all** rejections.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 48-57 are rejected under 35 U.S.C. 103(a) as being unpatentable over Eshhar et al PNAS vol. 90 p. 720 (1/1993), WO 92/15322, Wagner et al, Biotechnology Therapeutics vol. 3 p. 81 (1992) and applicant's admission on page 22(lines 10-24) of

the specification, and further in view of Hansen et al, Cancer vol. 71 p. 2478 (1993).

Since claims 48-57 are the same as 30-37, claims 48-57 are subject to the same rejection as indicated in paper no. 6, mailed 10/26/01.

Applicant argues that the motivation to combine the references comes from hindsight reasoning. Eshhar et al clearly suggests the use of chimeric genes in adoptive immunotherapy. In view of this suggestion combined with the disclosure of the WO which shows that such chimeric genes can be used in diseases caused by either tumors or infectious agents, it would have been obvious to use the chimeric genes of Eshhar et al in adoptive immunotherapy to treat tumors and infectious diseases. The motivation comes from the suggestion in the Eshhar et al reference and is not based on hindsight reasoning.

Applicant argues that in a 1990 reference Eshhar et al teach away from the use of cellular arms of the immune system. Applicant has mischaracterized the reference. The statement that applicant is referring to Eshhar's discussion of a paper by Hellstrom and Hellstrom, 1969). Thus, in 1969, applicant's statement is true. However, as evidence in the paragraph immediately following (Eshhar et al, 1990), Eshhar et al goes on to show many different groups have gone on to recruit the cellular arm and ultimately conclude with their work, which clearly employs the induction of the cellular arm. In fact, a fair reading of both the 1990 reference and the Eshhar et al reference used in the rejection clearly discuss the induction of the cellular arm. Specifically, on page 724 of the Eshhar et al, 1993 reference, first column, third full paragraph,

Application/Control Number: 09/688,089

Art Unit: 1642

discusses the different types of cells that can be used, and these include NK cells, LAK, cytotoxic T cells, to name a few.

Applicant argues that none of the references discuss humanizing antibodies. Applicant is arguing limitations not in the claims.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheela J Huff whose telephone number is 703-305-7866. The examiner can normally be reached on M,Th 5:30 am-2:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached on 703-308-3995. The fax phone numbers for the organization where this application or proceeding is assigned are 703-

Art Unit: 1642

308-4242 for regular communications and 703-308-4242 for After Final
communications.

Any inquiry of a general nature or relating to the status of this application or
proceeding should be directed to the receptionist whose telephone number is 703-308-
1235.


Sheela J. Huff
Primary Examiner
Art Unit 1642

sjh
July 8, 2002